[1]李红莉,贾红红.血清抗PLA2R抗体、增殖诱导配体、24 h尿蛋白水平联合检测在特发性膜性肾病中的应用价值[J].陕西医学杂志,2023,52(1):93-96.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.022]
　LI Hongli,JIA Honghong.Application value of combined detection of serum anti PLA2R antibody,proliferation inducing ligand and 24-hour urinary protein in idiopathic membranous nephropathy[J].,2023,52(1):93-96.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.022]
点击复制

血清抗PLA2R抗体、增殖诱导配体、24 h尿蛋白水平联合检测在特发性膜性肾病中的应用价值
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年1期
页码:
93-96
栏目:
临床检验
出版日期:
2023-01-05

文章信息/Info

Title:
Application value of combined detection of serum anti PLA2R antibody,proliferation inducing ligand and 24-hour urinary protein in idiopathic membranous nephropathy
作者:
李红莉; 贾红红
(延安市人民医院肾内科,陕西 延安 716000)
Author(s):
LI Hongli; JIA Honghong
(Department of Nephrology,Yan'an People's Hospital,Yan'an 716000,China)
关键词:
特发性膜性肾病;  血清抗PLA2R抗体;  增殖诱导配体;  24 h尿蛋白水平;  应用价值
Keywords:
Idiopathic membranous nephropathy;  Serum anti PLA2R antibody;  Proliferation inducing ligand;  24-hour urine protein level;  Application value
分类号:
R 692
DOI:
DOI:10.3969/j.issn.1000-7377.2023.01.022
文献标志码:
A
摘要:
目的:探究在特发性膜性肾病中采用血清抗PLA2R抗体、增殖诱导配体(APRIL)、24 h尿蛋白水平联合检测的应用价值。方法:研究对象为80例特发性膜性肾病患者与30例进行体检健康者。回顾80例患者的病历资料,所有患者的病情均经肾穿刺活检病理检查确诊,并按病理分期分为3组,即病理分期为1期者为观察A组(25例),病理分期为2期者为观察B组(30例),病理分期为3期者为观察C组(25例),健康体检者为对照组。四组参与研究者,均开展血清抗PLA2R抗体、增殖诱导配体(APRIL)、24 h尿蛋白水平检测,对比四组血清抗PLA2R抗体、增殖诱导配体(APRIL)、24 h尿蛋白水平,同时评估联合检测在特发性膜性肾病中的应用价值。结果:特发性膜性肾病患者的抗PLA2R抗体、APRIL、24 h尿蛋白水平明显高于对照组相应指标水平,比较差异具有统计学意义(均P<0.05); 三组患者的血清抗PLA2R抗体、APRIL、24 h尿蛋白水平比较差异无统计学意义(均P>0.05),其中观察C组患者以上指标高于观察1、2组,观察B组患者以上指标高于观察A组,比较差异均具有统计学意义(均P<0.05); 血清抗PLA2R抗体表达越高,患者的APRIL、24 h尿蛋白水平越高,之间存在明显的正相关关系,比较差异具有统计学意义(均P<0.05)。结论:特发性膜性肾病采用血清抗PLA2R抗体、增殖诱导配体(APRIL)、24 h尿蛋白水平联合检测,不仅可以检测出相关病情,还可以对病情的严重程度进行鉴别诊断。
Abstract:
Objective:To explore the application value of combined detection of serum anti PLA2R antibody,proliferation inducing ligand(APRIL)and 24-hour urinary protein in idiopathic membranous nephropathy.Methods:A total of 80 patients with idiopathic membranous nephropathy and 30 healthy subjects were studied.The medical records of 80 patients were reviewed.All patients' conditions were confirmed by pathological examination of renal puncture biopsy,and were divided into three groups according to pathological stages,that was,those with pathological stage 1 were observation group 1(25 cases),and those with pathological stage 2 were observation group 2(30 cases),and those with pathological stage 3 were the observation group(25 cases),and the healthy people were the control group.For all the four groups of participants,the detection of serum anti PLA2R antibody,APRIL and 24-hour urinary protein levels were carried out.The levels of serum anti PLA2R antibody,APRIL and 24-hour urinary protein in the four groups were compared.The application value of the combined detection in idiopathic membranous nephropathy was evaluated.Results:The levels of anti PLA2R antibody,APRIL and 24-hour urinary protein in patients with idiopathic membranous nephropathy were significantly higher than those in the control group(all P<0.05).There was no significant difference in the levels of serum anti PLA2R antibody,APRIL and 24-hour urinary protein among observation group 1,2 and 3(all P>0.05).The above indexes in the observation group 3 were higher than those in the observation group 1 and 2,and the above indexes in the observation group 2 were higher than those in the observation group 1(all P<0.05).The higher the expression of anti PLA2R antibody in serum,the higher the levels of APRIL and 24-hour urinary protein in patients,and there was a significant positive correlation between them(all P<0.05).Conclusion:The combined detection of serum anti PLA2R antibody,APRIL and 24-hour urinary protein in idiopathic membranous nephropathy can not only detect the relevant condition,but also differentiate and diagnose the severity of the condition.

参考文献/References:

[1] 李 强,张 全,冯 威,等.血清PLA2R抗体、KIM-1和Hcy联合检测在特发性膜性肾病患者诊断中的临床价值[J].临床血液学杂志,2022,35(6):398-401.
[2] Liu T,Xia M,Zhang Y,et al.The role of adiponectin and its receptor in patients with idiopathic membranous nephropathy complicated with hyperuricemia[J].Srpski Arhiv Za Celokupno Lekarstvo,2021,149(1):311-314.
[3] I Nietogaán,Rita CG,Perez JV,et al.Comparison of 3 anti-PLA2R inmmunoassaysfor the diagnosis of idiopathic membranous nephropathy in an european population:A pilot study[J].Clinical Immunology,2021,227(8):108729.
[4] 林 倩,朱义芳,刘婷莉,等.特发性膜性肾病患者血清增殖诱导配体水平与临床病理指标及预后的关系[J].国际检验医学杂志,2022,43(9):1115-1119.
[5] Wang Q,Dong ZY,Zhang WG,et al.Diagnostic efficacy of serum anti-phospholipase A2 receptor antibodies for idiopathic membranous nephropathy in patients with diabetic kidney disease[J].Clinica Chimica Acta,2020,502(3):222-226.
[6] 涂天琪,郑旭敏,杨 悦,等.血清抗磷脂酶A2受体抗体水平在乙型肝炎病毒相关膜性肾病诊断及预后评估中的价值[J].中华实用诊断与治疗杂志,2021,35(1):7-10.
[7] Tai YT,Acharya C,Gang A,et al.A novel anti-a proliferation-inducing ligand hapril a monoclonal antibody targets multiple myeloma cells in the bone marrow microenvironment[J].Cancer Research,2015,75(15):394-396.
[8] Lin L,Cho SF,Wen K,et al.Impacts of a proliferation-inducing ligand on current therapeutic monoclonal antibody-induced cytotoxicity against human multiple myeloma cells[J].Blood,2019,134(1):3105-3107.
[9] Jin Y,Zhang J,Wang Y,et al.Tripterygium wilfordii multiglycosides combined with prednisone in the treatment of idiopathic membranous nephropathy:A protocol for a systematic review and meta-analysis[J].Medicine,2020,99(5):e18970.
[10] Guo W,Zhang Y,Gao C,et al.Retrospective study:Clinicopathological features and prognosis of idiopathic membranous nephropathy with seronegative anti-phospholipase A2 receptor antibody[J].Peer J,2020,8(2):e8650.
[11] 乌 云,严怀秀,樊 迪,等.硼替佐米治疗肾功能不全多发性骨髓瘤患者的临床疗效及对Scr、BUN和24 h尿蛋白量的影响[J].中国病案,2021,22(12):109-113.
[12] Li Y,Long J,Chen J,et al.Analysis of spatiotemporal urine protein dynamics to identify new biomarkers for sepsis-induced acute kidney injury[J].Frontiers in Physiology,2020,11(3):139.
[13] 涂天琪,郑旭敏,杨 悦,等.血清抗磷脂酶A2受体抗体水平在乙型肝炎病毒相关膜性肾病诊断及预后评估中的价值[J].中华实用诊断与治疗杂志,2021,35(1):7-10.
[14] Jianming X,Yuxian B,Huichuan S,et al.A single-arm,multicenter,open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer[J].Cancer,2021,127(21):3975-3984.
[15] 宋 雪,罗 慧,赵甜甜.特发性膜性肾病中血清Chemerin和抗PLA2R抗体水平与病情的关系[J].热带医学杂志,2021,21(1):94-98.
[16] Wei SY,Wang YX,Li JS,et al.Serum Anti-PLA2R antibody predicts treatment outcome in idiopathic membranous nephropathy[J].American Journal of Nephrology,2016,43(2):129-140.
[17] 权浩浩,于小勇,程小红,等.血清抗M型磷脂酶A2受体抗体检测在膜性肾病诊断中的价值研究[J].陕西医学杂志,2020,49(6):755-758.
[18] 艾丽曼,王 顺.雷公藤多苷联合小剂量激素治疗特发性膜性肾病疗效研究[J].陕西中医,2022,43(6):712-714.
[19] 周 俊,曾秀琴,郭 芬.血清抗磷脂酶A2受体抗体在特发性膜性肾病诊断和治疗效果评价中的价值分析[J].内科,2020,15(1):17-19,25.
[20] 金 娟,任 燕,龚建光,等.血清抗磷脂酶A2受体抗体在特发性膜性肾病中的应用价值及与临床相关性探讨[J].中华全科医学,2020,18(2):208-212.

相似文献/References:

[1]蒋欣宇,李现成,程小红.环孢素A治疗特发性膜性肾病疗效和安全性系统评价Meta分析[J].陕西医学杂志,2021,50(10):1303.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.033]
　JIANG Xinyu,LI Xiancheng,CHENG Xiaohong.Systematic review and meta-analysis of the efficacy and safety of cyclosporine A in treatment of idiopathic membranous nephropathy[J].,2021,50(1):1303.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.033]

备注/Memo

备注/Memo:
基金项目:陕西省延安市科技惠民计划项目(2017HM-07-04)
更新日期/Last Update: 2022-12-28